RxDoctor Payments DataLook up a doctor →

Kendell Sogliero

Primary Care · Smithfield, PANPI 1720654932

Payments from drug & device makers

$9,231in general payments, 2019–2025

Across 600 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$931
  • Lilly USA, LLC$896
  • AstraZeneca$875
  • GSK$874
  • Boehringer Ingelheim$857
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,231 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.

See all primary care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,476
Medicare patients
181
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$44,830
FarxigaDapagliflozin Propanediol17$21,658
OzempicSemaglutide19$18,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,673
JardianceEmpagliflozin17$12,919
Montelukast Sodium39$740
Duloxetine Hcl25$716
Olmesartan Medoxomil42$672
Gabapentin20$647
Albuterol Sulfate HfaAlbuterol Sulfate16$593
Levothyroxine Sodium58$575
Ondansetron OdtOndansetron15$498
Rosuvastatin Calcium59$493
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$493
Atorvastatin Calcium60$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$556$44,83052 claims
AstraZenecaFarxiga$875$21,65817 claims
Novo NordiskOzempic$1,073$18,01619 claims
GSKTrelegy Ellipta$874$13,67314 claims
Boehringer IngelheimJardiance$857$12,91917 claims
Almatica Pharma LLCSertraline Hcl$14$26649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.

Other primary care in Smithfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →